Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.

News

ESMO Annual Meeting 2019: Menarini Ricerche presents the preclinical characterization of MEN1611, a novel PI3K inhibitor in development for the treatm
Promising results from the  preclinical study conducted by Menarini Ricerche on  MEN1611 , a potent and selective orally available phosphatidylinositol 3-kinase (PI3K) inhibitor currently in development  for the treatment ...
Menarini:  Elcin Barker Ergun Group CEO
The Board of Directors has appointed Mrs.  Elcin Barker Ergun   as CEO of Menarini Group.
Menarini Ricerche announces publication of pre-clinical data of the first-in-class antibody-drug conjugate MEN1309/OBT076,
Menarini Ricerche today announced the publication of the results of a non-clinical study describing the characterization of the anti-CD205 Antibody-Drug Conjugate (ADC)  MEN1309 /OBT076. These findings have been published by...

Menarini in the world

The Menarini Group has companies located almost all over the world.

READ MORE »

Diagnostics

Advanced technology.

READ MORE »

Our values

 

10 core values have influenced the progress of our group.

READ MORE »

Open positions

We are looking for talented people. Discover the opportunities!!

READ MORE »